However, hyperglycemia impaired the peak shortening, while Mfn2 siRNA treatment improved it, suggesting that Mfn2 silencing could normalize cardiomyocyte contractility under hyperglycemic conditions. Here, MFN2 is linked to Hyperglycemia.